CBT 1401A
Alternative Names: CBT-1401ALatest Information Update: 28 Aug 2022
At a glance
- Originator Centeer BioTherapeutics
- Class Proteins
- Mechanism of Action Fibroblast growth factor receptor agonists; Lipid metabolism modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Fatty liver
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for research development in Fatty liver in USA
- 31 Jul 2018 CBT 1401A is available for licensing as of 31 Jul 2018
- 31 Jul 2018 Early research in Fatty liver in USA